Market Eyes LiveRXO, Inc. (RXO) Stock Rating & Analysis
MELANY's data-driven read on RXO, Inc..
Why RXO scores 67/100
MELANY scores RXO, Inc. 67/100 by weighing eight factors. Here is how RXO breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
Margins, returns on capital, and balance-sheet strength.
Direction and relative strength of the recent share-price trend.
- Price +6.7% above 50-day MA
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Earnings in 13 days (strong beat history)
What Wall Street price targets and revisions are signalling.
- Institutional net buying +14.3%
Near-term events that could move the stock.
- Earnings in 13 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for RXO
- Short interest 26% of float, high volatility risk on news
- High beta 1.9, amplifies market drawdowns 1.8x+ in selloffs
- Trading near 52-week high, limited upside without new positive catalyst
- No positive trailing earnings, valuation cannot be anchored to current P/E
Sector and theme context
RXO, Inc. sits in the Industrials sector theme, which MELANY currently rates 68/100 for strength. Theme strength feeds RXO's momentum and catalyst factors above.
RXO trade plan (members only)
MELANY has a full position plan for RXO, Inc.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It unlocks free when you create an account.
How MELANY rates RXO
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. RXO, Inc.'s 67/100 reflects speculative factor weighting for its profile. Long-horizon position framework with quarterly score-based check-ins.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about RXO
Is RXO, Inc. (RXO) a buy?
As of 2026-07-24, MELANY rated RXO, Inc. Favorable with a composite score of 67/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is RXO, Inc.'s MELANY score?
RXO, Inc. (RXO) has a MELANY composite score of 67/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the RXO stock rating calculated?
MELANY scores RXO from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy RXO, Inc. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates RXO, Inc. (RXO) Favorable with a composite of 67/100 as of 2026-07-24. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the RXO stock price forecast?
MELANY does not publish price targets or forecasts for RXO. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 67/100 across eight factors for RXO, Inc., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is RXO stock overvalued or undervalued?
MELANY's valuation factor currently reads 22/100 for RXO, Inc., where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives RXO's read.
What price should I buy RXO at?
Rather than chasing the current price, MELANY computes a smart entry zone for RXO: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels unlock free when you create a Market Eyes Live account.
What are the risks of buying RXO stock?
The top risks MELANY currently flags for RXO, Inc.: Short interest 26% of float, high volatility risk on news; High beta 1.9, amplifies market drawdowns 1.8x+ in selloffs; Trading near 52-week high, limited upside without new positive catalyst; No positive trailing earnings, valuation cannot be anchored to current P/E. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is RXO, Inc. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 28/100 for RXO, Inc., and earnings track record, at 66/100. The 67/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will RXO stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 77/100 for RXO right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this RXO rating?
The rating on this page is a snapshot of MELANY's read as of 2026-07-24. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores RXO continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
RXO's entry zone, live alerts, and full trade plan are free either way. The app is our flagship.